Novel Therapies for Orphan Diseases.

"Orphan" does not mean infrequent: over 7000 rare diseases affect millions of individuals. The US Orphan Drug Act and analogous regulations have succeeded at accelerating the development of novel therapies, but high prices threaten sustainability. Lysosomal storage disorders serve here to illustrate the light and shadows of this burgeoning field.

[1]  C. Ferreira,et al.  The burden of rare diseases , 2019, American journal of medical genetics. Part A.

[2]  P. Saftig,et al.  Lysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases , 2019, Journal of Cell Science.

[3]  M. Mamdani,et al.  Estimating the clinical cost of drug development for orphan versus non-orphan drugs , 2019, Orphanet Journal of Rare Diseases.

[4]  Michael L Lanthier,et al.  Investigating the landscape of US orphan product approvals , 2018, Orphanet Journal of Rare Diseases.

[5]  Ana Mingorance.  Drivers of Orphan Drug Development. , 2018, ACS medicinal chemistry letters.

[6]  S. Simoens,et al.  Outrageous prices of orphan drugs: a call for collaboration , 2018, The Lancet.

[7]  F. Platt.  Emptying the stores: lysosomal diseases and therapeutic strategies , 2017, Nature Reviews Drug Discovery.

[8]  E. Sánchez-Fernández,et al.  Glycomimetic-Based Pharmacological Chaperones for Lysosomal Storage Disorders: Lessons from Gaucher, GM1-Gangliosidosis and Fabry Diseases , 2016 .

[9]  J. G. García Fernández,et al.  Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. , 2016, Chemical communications.

[10]  Yoshiyuki Suzuki.  Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease , 2013, Brain and Development.

[11]  R. Brady.  Enzyme replacement for lysosomal diseases. , 2006, Annual review of medicine.